|
Abrisqueta M, Cerdido S, Sanchez-Beltran J, Martinez-Vicente I, Herraiz C, Lambertos A, Olivares C, Sevilla A, Alonso S, Boyano MD, Garcia-Borron JC, Jimenez-Cervantes C. MGRN1 as a Phenotypic Determinant of Human Melanoma Cells and a Potential Biomarker. Life (Basel). 2022 Jul 26;12(8):1118. doi: 10.3390/life12081118. PubMed PMID: 35892921; PubMed Central PMCID: PMC9331370.
AÑO: 2022; IF: 3.251
|
35892921
|
Cerdido S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, Castejon-Grinan M, Munoz C, Olivares C, Garcia-Borron JC, Jimenez-Cervantes C, Herraiz C. MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42. Cancer Lett. 2024 Jan 28;581:216484. doi: 10.1016/j.canlet.2023.216484. Epub 2023 Nov 25. PubMed PMID: 38008393.
AÑO: 2024; IF: 9.1
|
|
Sanchez-Beltran J, Soler Diaz J, Herraiz C, Olivares C, Cerdido S, Cerezuela-Fuentes P, Garcia-Borron JC, Jimenez-Cervantes C. An MGRN1-Based Biomarker Combination Accurately Predicts Melanoma Patient Survival. Int J Mol Sci. 2025 Feb 18;26(4):1739. doi: 10.3390/ijms26041739. PubMed PMID: 40004203; PubMed Central PMCID: PMC11855888.
AÑO: 2025; IF: 4.9
|
|
Cerdido S, Sanchez-Beltran J, Lambertos A, Abrisqueta M, Padilla L, Herraiz C, Olivares C, Jimenez-Cervantes C, Garcia-Borron JC. A Side-by-Side Comparison of Wildtype and Variant Melanocortin 1 Receptor Signaling with Emphasis on Protection against Oxidative Damage to DNA. Int J Mol Sci. 2023 Sep 21;24(18):14381. doi: 10.3390/ijms241814381. PubMed PMID: 37762683; PubMed Central PMCID: PMC10532403.
AÑO: 2023; IF: 4.9
|